City of Hope's Impact

Since its founding in 1913, City of Hope has continued to evolve to expand hope to meet the growing needs of patients. Created initially by a group of volunteers committed to providing care and dignity for tuberculosis patients, the institution shifted its focus to cancer in the 1950s when tuberculosis was no longer a threat.
City of Hope has grown into a national leader in cancer and one of the most productive high-impact biomedical research enterprises in the areas of cancer and diabetes. City of Hope is a National Cancer Institute-designated comprehensive cancer center, the highest designation possible from the National Cancer Institute.
As City of Hope moves into its second century, we are ready to answer the call to bring leading-edge, personalized care and scientific innovation to greater numbers of people. By broadening access and increasing capacity for scientific discovery and clinical research, we are expanding hope for the future of health.
City of Hope’s impact extends beyond its main campus and research center located in Southern California. Numerous breakthrough cancer drugs, including Herceptin, Erbitux, Rituxan and Avastin, are based on technology pioneered by City of Hope, and are saving lives worldwide. Furthermore, millions of people with diabetes benefit from synthetic human insulin, developed through research conducted at City of Hope.